United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 11,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 11,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $484.67, for a total transaction of $5,331,370.00. Following the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $17,826,647.27. This represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Trading Up 1.1%

Shares of UTHR stock opened at $493.99 on Friday. The company has a market cap of $21.27 billion, a PE ratio of 18.72, a P/E/G ratio of 4.85 and a beta of 0.86. The company’s fifty day simple moving average is $457.81 and its 200-day simple moving average is $374.01. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $496.73.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same period in the prior year, the company earned $6.39 EPS. The firm’s revenue was up 6.8% on a year-over-year basis. Equities research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Several institutional investors have recently added to or reduced their stakes in UTHR. Darwin Global Management Ltd. acquired a new position in United Therapeutics during the 3rd quarter worth $317,617,000. Norges Bank bought a new position in shares of United Therapeutics during the second quarter worth about $136,453,000. Invesco Ltd. grew its stake in United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares in the last quarter. AQR Capital Management LLC increased its holdings in United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after buying an additional 364,713 shares during the last quarter. Finally, Amundi increased its holdings in United Therapeutics by 198.8% in the first quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock valued at $107,635,000 after buying an additional 232,988 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on UTHR shares. Oppenheimer raised their target price on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Bank of America lifted their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a report on Wednesday, October 29th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $505.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.